
    
      THE MAIN OBJECTIVE of this study is to evaluate the efficacy and safety of the subcutaneous
      administration of Bemiparin 3,500 IU, for the peri-operative procedural management of
      patients requiring temporary interruption of oral anticoagulation therapy (OAT).

      PRIMARY EFFICACY ENDPOINT: combined incidence of arterial and venous thromboembolic events
      and deaths from any causes within 3 months after the invasive procedure.

      PRIMARY SAFETY ENDPOINT: incidence of major bleeding within 10 days after the invasive
      procedure.
    
  